ClinicalTrials.Veeva

Menu

Prevalence and Hematological Characteristics of Hemoglobinopathies

B

Bacha Khan Medical College

Status

Completed

Conditions

Hemoglobinopathies

Treatments

Other: No Intervention (Observational Study)

Study type

Observational

Funder types

Other

Identifiers

NCT07180836
Ref no. 499/BKMC

Details and patient eligibility

About

This study aimed to determine the prevalence and hematological characteristics of hemoglobinopathies in Mardan and surrounding districts of Khyber Pakhtunkhwa (KPK), Pakistan. A descriptive cross-sectional design was conducted at Mardan Medical Complex from January 2021 to January 2023. Blood samples were analyzed using High Performance Liquid Chromatography (HPLC) on the Bio-Rad D-10 analyzer, with complete blood counts performed using Sysmex XN1000. A total of 839 participants were enrolled in this study. The study highlights differences in hematological parameters across hemoglobinopathy types and provides region-specific data to inform public health interventions and screening programs.

Full description

Hemoglobinopathies are among the most common inherited disorders worldwide, caused by mutations in globin genes affecting hemoglobin synthesis, structure, and function. They are highly prevalent in South Asia, particularly in Pakistan, where beta-thalassemia is the most frequent single-gene disorder. Despite this, there is limited epidemiological data from Khyber Pakhtunkhwa (KPK), especially in Mardan, where consanguineous marriages are common and contribute to disease burden.

This descriptive cross-sectional study was conducted over a two-year period (January 2021 to January 2023) at the hematology department of Mardan Medical Complex, Pakistan. All patients referred for hemoglobinopathy testing were included. Blood samples (3 mL EDTA) were collected and analyzed for complete blood counts (hemoglobin, RBC count, hematocrit, MCV, MCH, MCHC) using Sysmex XN1000, and hemoglobin variants were identified using High Performance Liquid Chromatography (Bio-Rad D-10 analyzer). A sickling test was performed in cases with abnormal S-window chromatogram findings.

A total of 839 participants were analyzed. Geographic distribution was showed for patients from different nearby regions .

This study provides the first comprehensive regional overview of hemoglobinopathies in Mardan, KPK. The findings of our study will emphasize the need for early detection, genetic counseling, and preventive public health strategies, particularly in communities with high rates of consanguinity. These results might support the development of targeted screening and awareness programs to reduce the burden of hemoglobinopathies in Pakistan.

Enrollment

839 patients

Sex

All

Ages

1 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients referred to the Hematology Department of Mardan Medical Complex for hemoglobinopathy testing between Jan 2021 - Jan 2023.
  • Patients of either sex.
  • Patients who underwent high-performance liquid chromatography (HPLC) and complete blood count (CBC) analysis.

Exclusion criteria

  • Patients with incomplete or missing laboratory data (CBC or HPLC).
  • Patients in whom hemoglobinopathy diagnosis could not be confirmed.
  • Cases of anemia due to non-hemoglobinopathy causes (e.g., nutritional anemia, chronic disease).

Trial design

839 participants in 1 patient group

Patients with Hemoglobinopathies in Mardan and Surrounding Districts
Description:
This cohort includes patients diagnosed with various hemoglobinopathies in Mardan and neighboring districts of Khyber Pakhtunkhwa, Pakistan. Participants were assessed for prevalence and hematological characteristics, including complete blood count parameters and disease-specific findings. No intervention was applied; this is an observational, cross-sectional study focused on identifying distribution patterns and hematological profiles of hemoglobinopathies in the study population
Treatment:
Other: No Intervention (Observational Study)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems